4/4/2014 8:08:43 AM
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. (NASDAQ: RTPT) to provide genetic testing services for Raptor’s clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.
Help employers find you! Check out all the jobs and post your resume.
comments powered by